WeTrials
Recruiting

A Phase 0/1 Study of BMS-986504, a MTA Cooperative PRMT5 Inhibitor in Recurrent Glioblastoma Participants With MTAP Deleted Tumors Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK-Triggered Expansion Cohort

What is this study?

This study tests a new medication called BMS-986504 in adults with a fast-growing brain tumor called recurrent glioblastoma. Researchers want to see how well the medicine enters the brain and if it is safe to use for tumors lacking a specific gene called MTAP.

Who can participate?

You may qualify if you are 18 or older, have a brain tumor that has returned after previous treatments like surgery and radiation, and genetic testing shows your tumor has the MTAP gene deletion. You must also be scheduled for surgery to remove the tumor and be healthy enough to undergo MRI scans.

What will happen?

Participants will take the study medication before a scheduled brain surgery so researchers can measure how well the drug reaches the tumor. If the drug reaches the tumor effectively, you may have the option to continue taking it in repeated treatment cycles.

Where and when?

This study is currently recruiting participants and takes place in Phoenix, Arizona, in the United States. Your care team will guide you through all the specific clinic visits and required medical tests.

Key Points
  • 1Tests a new investigational medication called BMS-986504 for a specific type of recurrent brain tumor.
  • 2Requires participants to have a confirmed loss of the MTAP gene in their tumor tissue.
  • 3Involves taking the medication leading up to a scheduled surgical removal of the tumor.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Glioblastoma WHO Grade IV

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.